GSK PLC (LSE:GSK)
£ 18.1 0.105 (0.58%) Market Cap: 73.81 Bil Enterprise Value: 87.49 Bil PE Ratio: 17.87 PB Ratio: 5.33 GF Score: 77/100

GlaxoSmithKline PLC at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2020 / 03:40PM GMT
Release Date Price: £15.44 (+2.67%)
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

Welcome back. Delighted to introduce our next session today. We have Hal Barron, the Chief Scientific Officer at GSK. We've got Jeff McLaughlin and other members of the GSK Investor Relation team. Pleasure to have you with us, Hal.

Questions & Answers

Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So look, I'm looking forward to a broad-ranging conversation. Given GSK is one of the preeminent vaccine manufacturers in the world and given we had news overnight of the suspension of one of your competitors' Phase III trial programs for COVID, as a way of segmenting into your COVID efforts, perhaps you can talk to how you would see the hurdle for safety to COVID. And I guess, general concept, because, obviously, we don't know the details and there's been some information that trial may restart. How many episodes of demyelination associated with a vaccine in a patient without preexisting conditions is enough to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot